Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Instil Bio Inc TIL

Instil Bio, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies. The Company seeks to in-license/acquire and develop novel therapeutic candidates in diseases with significant unmet medical need. Its first such program is an engineered tumor infiltrating lymphocyte (TIL), cell therapy for the treatment of cancer. It is engaged in developing a novel class of genetically engineered TIL therapies using its Co-Stimulatory Antigen Receptor (CoStAR), platform. The Company's lead CoStAR-TIL product candidate, ITIL-306, expresses a CoStAR molecule designed to recognize folate receptor alpha (Fra), a tumor-associated antigen that is expressed on numerous solid tumors, including ovarian cancer, uterine cancer, NSCLC and renal cancer. CAR-T and TCR-T therapies are cell products composed of T cells that have been genetically engineered to recognize a specific cancer-related antigen on the surface of tumor cells.


NDAQ:TIL - Post by User

Bullboard Posts
Comment by kaosblueson Feb 16, 2012 7:32pm
317 Views
Post# 19546570

RE: GPD hold

RE: GPD hold

Hey Vendy: 

Wake up and smell the coffee or at least get with the program.  Didn't you see the media release, GPD now has 100% of the Brewery Creek project.  If they were to file an NI-43 during the past few weeks knowing this possible change was imminent they could have been open to attack for misleading shareholders.  Don't confuse companies that have something to hide with this one. In my opinion you clearly are either missing the facts or are simply out to lunch with regard to your posting in respect of this company.

This was fabulous news regardless of how the market responds in the short term.  In the medium term it will correct itself as investors see the light, of that I am dead certain.

Bullboard Posts